Core Viewpoint - Qingdao Guoen Technology Co., Ltd. has officially submitted its listing application to the Hong Kong Stock Exchange, marking a significant step in its capital market strategy and aiming to enhance its international influence and competitiveness [1] Group 1: Company Overview - Guoen Technology is a comprehensive enterprise group driven by technological innovation, focusing on long-term scale efficiency and implementing a "one body, two wings" development strategy in the large chemical and health industries [2] - In the large chemical sector, Guoen Technology is the second-largest organic polymer material modification producer in China and the largest producer of polystyrene, showcasing its strong market position [2] - In the health industry, Guoen Technology's subsidiary Dongbao Biological has established a comprehensive product layout from collagen to "collagen +", becoming a significant player in the health sector [3] Group 2: Financial Performance - The company has shown strong revenue growth, with total revenues of approximately RMB 134.06 billion, RMB 174.39 billion, and RMB 191.88 billion for the fiscal years 2022, 2023, and 2024, respectively [4] - The main revenue source is the large chemical sector, contributing RMB 183.3 billion in 2024, accounting for 95.6% of total revenue, while the health sector contributed RMB 8.53 billion, representing 4.4% of total revenue [5] - The overall gross profit margins for the fiscal years 2022, 2023, and 2024 were 11.8%, 9.2%, and 8.3%, respectively, with the health sector showing a higher margin of 23.2% in 2024 [6] Group 3: Future Prospects - The successful listing on the Hong Kong Stock Exchange is expected to provide new development opportunities for the company, allowing it to expand capacity, increase R&D investment, and enhance its domestic and international market presence [6] - The company's strong foundation in the large chemical and health sectors, along with its financial performance and future growth potential, positions it as a noteworthy investment opportunity [7]

Core Viewpoint - Guoen Technology is a comprehensive enterprise group driven by technological innovation, focusing on long-term scale efficiency and implementing a "one body, two wings" development strategy in the large chemical and health industries [2]. Group 1: Industry Overview - In the large chemical industry, Guoen Technology is deeply engaged in the chemical new materials industry chain, building a "new materials+" ecosystem and enhancing its vertical integration layout [2]. - The company is the second-largest organic polymer material modification producer in China by revenue in 2024 and the largest producer of polystyrene by capacity [2]. - In the health industry, Guoen Technology focuses on the natural collagen industry, establishing a vertically integrated product layout from animal collagen to end products [2][3]. Group 2: Financial Performance - For the fiscal years 2022, 2023, and 2024, Guoen Technology reported total revenues of approximately RMB 13.406 billion, RMB 17.438 billion, and RMB 19.188 billion respectively [3][5]. - The net profit for the same periods was approximately RMB 724 million, RMB 540 million, and RMB 721 million respectively [3][5]. - The gross profit figures for the fiscal years were RMB 1.580 billion, RMB 1.601 billion, and RMB 1.592 billion respectively, indicating a stable gross profit margin [5].

序号股票简称PE(TTM)PE(静)市净率总市值(元)13黄山胶囊40.9843.912.3121.62亿行业平均 49.1247.184.49104.96亿行业中值36.0737.112.4149.03亿1英科医疗9.6910.450.86153.16亿2九安医疗 10.1410.250.80171.07亿3新华医疗14.2913.251.1791.61亿4奥美医疗15.1114.811.5554.59亿5康德莱 15.2015.211.2632.76亿6振德医疗15.4114.520.9855.93亿7山东药玻15.5915.641.79147.46亿8维力医疗 16.0516.691.8836.61亿9奥泰生物16.1917.071.3151.64亿10九强生物16.3315.192.0080.89亿11安杰思 17.2317.442.0851.16亿12三鑫医疗18.3518.353.0241.74亿 来源：金融界 安徽黄山胶囊股份有限公司的主营业务是明胶空心胶囊和肠溶明胶空心胶囊的研发、生产与销售。公司 的主要产品是明胶空心胶囊、肠溶明胶空心胶囊、羟丙甲纤维素空心胶囊、普鲁兰多糖空心胶囊。公司 是中 ...

限公司向不特定对象发行可转换 公司债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【87】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客 观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经 ...

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均50.64倍，行业中值37.05倍，黄山胶囊排 名第84位。 6月9日，黄山胶囊今日收盘7.41元，上涨1.51%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到42.00倍，创325天以来新低，总市值22.16亿元。 安徽黄山胶囊股份有限公司的主营业务是明胶空心胶囊和肠溶明胶空心胶囊的研发、生产与销售。公司 的主要产品是明胶空心胶囊、肠溶明胶空心胶囊、羟丙甲纤维素空心胶囊、普鲁兰多糖空心胶囊。公司 是中国最早的药用空心胶囊生产企业之一，拥有三十多年高品质药用空心胶囊生产历史。在药用空心胶 囊行业，公司具有较高的知名度，现为中国医药包装协会突出贡献奖成员单位、药用空心胶囊专业委员 会副主任单位之一。公司的商标被评为安徽省著名商标，"旌川"牌药用空心胶囊获"安徽名牌产品"称 号。"旌川"牌明胶空心胶囊和肠溶明胶空心胶囊荣获"中国化学制药行业药用辅料优秀产品品牌"。 最新一期业绩显示，2025年一季报，公司实现营业收入1.19亿元，同比0.53%；净利润1883.70万元，同 比22.90%，销售毛利率29.26%。 序号股票简称PE(TTM)P ...

Group 1 - Guangdong Province has initiated a centralized procurement program involving 170 drug varieties and 248 specifications, which may lead to lower drug prices and industry consolidation [1] - The procurement process eliminates A/B procurement orders and adopts group bidding [1] Group 2 - Shandong Heda's subsidiary has been preliminarily assessed with an anti-dumping tax rate of 172.24% by the U.S. Department of Commerce, affecting its exports to the U.S. market [2] - Other Chinese manufacturers/exporters face anti-dumping tax rates ranging from 5.4% to 88.82% [2] - The final ruling on the anti-dumping and countervailing investigation is expected to be released in October 2025, which may impact the company's market strategy [2] Group 3 - The Xinjiang Market Supervision Administration has published five typical cases of violations in the medical field, highlighting issues such as illegal charging and unlicensed drug sales [3] - The penalties imposed include fines for hospitals and pharmaceutical companies, indicating a strict regulatory environment aimed at ensuring compliance and protecting public interests [3]

Core Viewpoint - Guoen Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international capital operation platform and accelerate the establishment of a dual circulation pattern in the domestic and international markets [1] Group 1: Company Overview - Guoen Co., Ltd. was established in 2000 and is headquartered in Qingdao, focusing on two core industries: large chemicals and health [1] - The company operates a vertically integrated industrial platform and implements a "one body, two wings" development strategy, forming a cluster of new chemical materials [1] - The company has a strong presence in the health sector through its subsidiary Dongbao Biological, which produces a variety of products including gelatin and collagen [1] Group 2: Chemical Industry Segment - The large chemical segment generated revenue of 17.369 billion yuan in 2024, accounting for 90.38% of total revenue, with a year-on-year growth of 11.62% [3] - The company has established long-term stable partnerships with major clients such as Hisense, Gree, TCL, Huawei, BOE, and CATL [3] - Current production capacities include 1.08 million tons for organic polymer modified materials, 400,000 tons for organic polymer composite materials, and 900,000 tons for green petrochemical materials [4] Group 3: Product Development and Market Strategy - The company is enhancing its market share in the new energy vehicle sector by improving the performance of modified materials such as PP, PC, ABS, and PA [2] - In the energy storage battery sector, the company is advancing the application of flame-retardant and anti-explosion materials [2] - Future plans include expanding production capacities for polystyrene and developing new products like high-performance polyolefin elastomers and biodegradable materials [5] Group 4: Financial Performance - In 2024, the health segment generated revenue of 885 million yuan, accounting for 4.6% of total revenue [5] - Overall, the company achieved a total revenue of 19.22 billion yuan in 2024, a year-on-year increase of 10.21%, with a net profit of 676 million yuan, up 45.18% [5] - The first quarter of 2025 reported total revenue of 4.412 billion yuan, a slight decrease of 0.23% year-on-year, with a net profit of 111 million yuan, down 9.79% [6]

在大化工产业领域，国恩股份全力打造以绿色石化材料、有机高分子改性材料、有机高分子复合材料为 主的三大业务引擎，多维度构建"新材料+"产业生态圈，不断完善大化工产业纵向一体化布局。 大健康产业领域，国恩股份子公司东宝生物专业从事明胶、胶原蛋白及其延伸品的研发、生产、销售， 为下游用户提供全面系统的产品及服务方案，产品运营方式分为To B端业务和To C端业务。在To B端业 务方面，主要包括明胶、代血浆明胶、空心胶囊、胶原蛋白等，主要应用于药用辅料、医用胶原、营养 大健康市场、美妆、医疗医美、新材料应用等领域；在To C端产品方面，拥有以天然胶原蛋白肽为基础 成分的"胶原+"系列营养健康品、美妆产品等，能够满足不断发展的健康市场需求。 国恩股份（002768）5月26日晚间公告，公司拟发行H股股票并申请于香港联交所主板挂牌上市。 国恩股份表示，赴港上市是为深入推进公司全球化战略布局，打造国际化资本运作平台，加快构建国内 国际双循环格局，进一步助推公司产业全球化布局升维。公司将充分考虑现有股东的利益和境内外资本 市场的情况，在股东大会决议有效期内(即经公司股东大会审议通过之日起18个月或同意延长的其他期 限)选择 ...

【DT新材料】 获悉，5月25日， 国恩股份 发布公告称， 公司于2025年5月26日召开董事会和监事 会，审议通过发行H股股票并在香港联交所主板挂牌上市的议案 。公司计划通过发行境外上市外资 股（H股）股票，打造国际化资本运作平台，加快构建国内国际双循环格局。 国恩股份 成立于2000年，总部位于青岛市城阳区青大工业园，是一家以 大化工 和 大健康 为两大核 心产业的上市公司。公司以国恩系纵向一体化产业平台为中枢，实施"一体两翼"发展战略，形成了绿 色石化、有机高分子改性、有机高分子复合材料、可降解材料、光显材料、运动健康材料以及新能源 汽车轻量化结构部品等化工新材料产业集群。 同时，控股胶原领域上市公司 东宝生物 ，通过明胶、 代血浆明胶、胶原蛋白、空心胶囊、双蛋白膳食纤维、美妆产品等在"医、美、健、食"的广泛应用， 深入布局大健康产业细分领域。 公 司 大化工板块 涵盖有机高分子改性材料、有机高分子复合材料、绿色石化材料及新材料等多个领 域， 通过技术创新和产品升级，形成了从通用改性材料到高端特种材料的矩阵化产品体系，广泛应 用于家电、汽车、新能源等领域。 在动力电池、储能电池等相关产业方向，加快推进 ...

Core Viewpoint - The company, Shandong Heda, faces significant challenges due to the preliminary anti-dumping and countervailing duties imposed by the U.S. Department of Commerce on hard empty capsules, with a notably high anti-dumping rate of 172.24% for its subsidiary, Hushi, compared to lower rates for other Chinese manufacturers [1][3]. Group 1: Anti-Dumping and Countervailing Duties - The U.S. Department of Commerce announced a preliminary affirmative ruling on May 22, 2025, regarding anti-dumping duties on hard empty capsules from Brazil, China, India, and Vietnam [1]. - Shandong Heda's subsidiary, Hushi, received an anti-dumping duty rate of 172.24%, significantly higher than the range of 5.4% to 88.82% for other Chinese manufacturers [3]. - The countervailing duty rate for Hushi was preliminarily set at 6.82%, while other Chinese producers faced rates between 3.45% and 8.53% [2][3]. Group 2: Impact on Sales and Revenue - During the investigation period from April 1, 2024, to September 30, 2024, sales of hard empty capsules to the U.S. accounted for 62.38% of the total revenue from this product line [2]. - For the countervailing duty investigation period from January 1, 2023, to December 31, 2023, sales to the U.S. represented 44.22% of the total revenue [2]. Group 3: Strategic Responses - The company has proactively built inventory in the U.S. to mitigate the impact of trade tensions, ensuring that current stock can meet U.S. market demand for 5 to 6 months [4]. - Shandong Heda is advancing a project to establish a plant in the U.S. with a capacity of 20 billion capsules per year, which is expected to be operational by 2026 [5]. - The company has formed a special task force and hired legal experts to navigate the dual investigations and aim for the most favorable duty rates [2][4]. Group 4: Financial Performance - In 2024, Shandong Heda reported overseas revenue of 1.232 billion yuan, with a gross margin of 30.67%, which, despite a decline, remains higher than the domestic gross margin of 20.72% [6].